加州大學戴維斯分校健康中心展開創新心臟輔助裝置臨床試驗
UC Davis Health Begins Trial of Innovative Heart Assist Device
Updated at: June 27, 2026 at 03:00 AM
加州大學戴維斯分校健康中心身為西美國首批參與「SUPPORT II 關鍵性研究」的醫院之一，正處於醫學創新的前沿。
UC Davis Health is at the forefront of medical innovation as one of the first hospitals in the Western United States to participate in the SUPPORT II Pivotal Study.
此項臨床試驗旨在評估 Supira 系統，這是一種具有突破性、低剖面的經皮心室輔助裝置 (pVAD)。
This clinical trial evaluates the Supira System, a groundbreaking, low-profile percutaneous ventricular assist device (pVAD).
與傳統較為笨重的機械支援設備不同，Supira 系統設計更為小巧，有助於減少血管併發症，並在複雜的心臟手術中為心臟科醫師提供更佳的操作空間。
Unlike traditional, bulkier mechanical supports, the Supira System is designed to be smaller, which helps reduce vascular complications and provides cardiologists with better access during complex heart procedures.
透過內建感測器，該裝置能夠對壓力進行即時監測，從而實現更精準的病患照護。
By using built-in sensors, the device offers real-time monitoring of pressure, allowing for more precise patient care.
這項技術對於嚴重心臟病患或心源性休克患者尤為重要，因為他們在進行如支架置入等救命手術時，需要血流動力學的支持。
This technology is particularly vital for patients with severe heart disease or those experiencing cardiogenic shock, who require hemodynamic support during life-saving interventions like stenting.
在 Garrett Wong 醫師與 Tai Pham 醫師的帶領下，加州大學戴維斯分校的團隊正為一項涵蓋全美 385 名病患的大型研究做出貢獻。
Led by Dr.
其終極目標是為過去被認為不適合動手術的高風險病患，提供更安全、更有效的治療選項。
Garrett Wong and Dr.
來自此項試驗的數據，將在食藥署 (FDA) 的核准流程中發揮關鍵作用，並有望在未來使此項技術成為全國心血管照護的標準配置。
Tai Pham, the UC Davis team is contributing to a larger study involving 385 patients nationwide.
